IN2014MN02236A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02236A
IN2014MN02236A IN2236MUN2014A IN2014MN02236A IN 2014MN02236 A IN2014MN02236 A IN 2014MN02236A IN 2236MUN2014 A IN2236MUN2014 A IN 2236MUN2014A IN 2014MN02236 A IN2014MN02236 A IN 2014MN02236A
Authority
IN
India
Prior art keywords
composition
aqueous
voriconazole
prevention
preparing
Prior art date
Application number
Other languages
English (en)
Inventor
Shrinivas Purandare
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to IN2236MUN2014 priority Critical patent/IN2014MN02236A/en
Publication of IN2014MN02236A publication Critical patent/IN2014MN02236A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN2236MUN2014 2012-05-11 2013-05-10 IN2014MN02236A (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2236MUN2014 IN2014MN02236A (fr) 2012-05-11 2013-05-10

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1444MU2012 2012-05-11
PCT/GB2013/000211 WO2013167865A1 (fr) 2012-05-11 2013-05-10 Composition pharmaceutique
IN2236MUN2014 IN2014MN02236A (fr) 2012-05-11 2013-05-10

Publications (1)

Publication Number Publication Date
IN2014MN02236A true IN2014MN02236A (fr) 2015-07-24

Family

ID=48485212

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2236MUN2014 IN2014MN02236A (fr) 2012-05-11 2013-05-10

Country Status (12)

Country Link
US (1) US20150133472A1 (fr)
EP (1) EP2846769A1 (fr)
JP (1) JP2015516409A (fr)
KR (1) KR20150028241A (fr)
CN (1) CN104519867A (fr)
AU (1) AU2013257830A1 (fr)
BR (1) BR112014028069A2 (fr)
CA (1) CA2872958A1 (fr)
IN (1) IN2014MN02236A (fr)
MX (1) MX2014013714A (fr)
RU (1) RU2014149993A (fr)
WO (1) WO2013167865A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3050298A1 (fr) 2012-08-24 2014-02-27 Sun Pharma Global Fze Formulation ophtalmique d'acide gras ou lipidique de polyoxyle et d'alcool de polyoxyethylene, et traitement de pathologies oculaires
JP2017519813A (ja) * 2014-05-23 2017-07-20 オキュラー テクノロジーズ エスアーエールエル 局所製剤およびその使用
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
WO2016182032A1 (fr) * 2015-05-12 2016-11-17 参天製薬株式会社 Administration d'un agent antifongique de type azole à la peau de la paupière
JP2018521000A (ja) 2015-05-29 2018-08-02 シドネキシス，インク． Ｄ２ｏで安定化された医薬製剤
US20190231885A1 (en) 2015-11-10 2019-08-01 Sun Pharma Global Fze Topical formulations and uses thereof
CN109843316A (zh) 2016-02-29 2019-06-04 太阳制药全球公司 含有环孢菌素的局部制剂及其用途
PT3266446T (pt) * 2016-07-07 2019-01-30 Salvat Lab Sa Composição oftálmica compreendendo óleo de rícino e triglicérido de cadeia média
CN106390130B (zh) * 2016-09-18 2018-06-01 中国人民解放军第二军医大学 烟酰胺作为抗真菌药物增效剂的用途
EP3706714B1 (fr) * 2017-11-06 2022-09-14 Dermalena Di Calderan Andrea Formulation à base de n-acétylcystéine et d'urée pour le traitement de troubles dermatologiques

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819308D0 (en) 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9002375D0 (en) 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
CA2443937A1 (fr) * 2001-04-23 2002-10-31 Randall D. Glickman Prostanoides pouvant augmenter la penetration de medicaments oculaires
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
US20050112204A1 (en) 2003-11-25 2005-05-26 Pfizer Inc. Pharmaceutical formulations
US9132071B2 (en) * 2006-07-28 2015-09-15 Santen Sas Compositions containing quaternary ammonium compounds
CN1962683A (zh) * 2006-12-18 2007-05-16 张文芳 聚乙二醇修饰的甾醇共聚物及其应用
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
EP2027850A1 (fr) * 2007-08-22 2009-02-25 Sandoz AG Compositions pharmaceutiques contenant du voriconazole
WO2011064558A2 (fr) * 2009-11-30 2011-06-03 Cipla Limited Composition pharmaceutique

Also Published As

Publication number Publication date
WO2013167865A1 (fr) 2013-11-14
US20150133472A1 (en) 2015-05-14
AU2013257830A1 (en) 2014-11-20
CA2872958A1 (fr) 2013-11-14
KR20150028241A (ko) 2015-03-13
EP2846769A1 (fr) 2015-03-18
MX2014013714A (es) 2015-08-10
BR112014028069A2 (pt) 2017-08-08
RU2014149993A (ru) 2016-07-10
JP2015516409A (ja) 2015-06-11
CN104519867A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
IN2014MN02236A (fr)
PH12016501122A1 (en) Delayed release compositions of linaclotide
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PH12016501790B1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
MX370543B (es) Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
IN2013MU03583A (fr)
GB201118656D0 (en) New compounds
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
PH12015501156A1 (en) Pharmaceutical compositions
IN2014DN10670A (fr)
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
WO2014033526A9 (fr) Compositions pharmaceutiques d'étoricoxib
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
IN2014DN03010A (fr)
MX2015011588A (es) Tratamiento de combinacion.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
GB201114923D0 (en) Immunogenic proteins and compositions
IN2014KN02584A (fr)
MX2012014498A (es) Composicion farmaceutica de rosuvastatina.
IN2013MU03838A (fr)
IN2013MU01160A (fr)